New gene signatures point to how M72/AS01E protects against tuberculosis

Tuberculosis remains a leading global killer, claiming around 1.5 million lives each year. The M72/AS01E vaccine candidate has shown promise, reducing the incidence of active TB by about 50% in adults, but improving and optimizing vaccination strategies depends on understanding the precise immune molecular signals that accompany protection. In work led by Oluwaseun Oluwatosin Taofeek, researchers returned to data from a Phase IIA clinical trial to look for those signals. They analyzed publicly available gene expression data from peripheral blood mononuclear cells taken from volunteers who received two doses of 10μg of M72/AS01E. Samples were collected one day after the second dose (D31) and one week after the second dose (D37). Rather than focusing on single genes, the team applied systems-level approaches — combining weighted gene co-expression network analysis, machine learning and network biology — to search for coordinated patterns of gene activity and regulatory relationships that might mark a protective immune response. The aim was to identify transcriptomic markers that could serve as potential correlates of vaccine protection and guide future TB vaccine development.

The study used a combination of computational tools to extract meaningful patterns from the trial data. Weighted gene co-expression network analysis revealed a strong, acute induction of multiple gene modules at D31, indicating an immediate immune response that largely subsided by D37. From these networks the team identified 31 hub genes whose expression was significantly elevated and correlated with immune protection; these genes were described as mediating key events in immunity to TB. By D37 a more selective profile emerged, pointing to engagement of adaptive immunity pathways including Th1/Th2/Th17 differentiation, T cell receptor and cytokine signaling. To test the predictive power of the identified markers, researchers applied a random forest classifier, which showed high accuracy in distinguishing vaccinated from non-vaccinated samples. The analysis was extended into regulatory space by constructing a miRNAs-transcription factors (TF)-target regulatory network, excavating key TF, miRNA, and mRNA interactions that may mediate the protective response to M72/AS01E.

These findings offer a clearer picture of how the immune system responds to M72/AS01E and point to measurable molecular signatures that could serve as correlates of protection. Identifying 31 hub genes and a connected miRNAs-transcription factors (TF)-target regulatory network suggests specific molecules and pathways to study further in larger trials and in different populations. If validated, these transcriptomic markers could help predict who is likely to mount a protective response, guide vaccine dosing and timing, and inform the design of next-generation TB vaccines. The distinction between an early, broad innate-like response at D31 and a more focused adaptive signature at D37 highlights the value of time-resolved sampling in vaccine studies. While additional experimental validation is needed, the systems and machine learning approach used by Oluwaseun Oluwatosin Taofeek and colleagues provides a roadmap for turning complex gene expression data into actionable insights for TB vaccine optimization and development.